



STERIS plc (STE)

Updated February 19th, 2025, by Yiannis Zourmpanos

Key Metrics

Current Price:	\$220	5 Year CAGR Estimate:	6.8%	Market Cap:	\$22.0 B
Fair Value Price:	\$228	5 Year Growth Estimate:	5.0%	Ex-Dividend Date:	02/20/2025
% Fair Value:	97%	5 Year Valuation Multiple Estimate:	0.7%	Dividend Payment Date:	03/21/2025
Dividend Yield:	1.0%	5 Year Price Target	\$290	Years Of Dividend Growth:	14
Dividend Risk Score:	A	Retirement Suitability Score:	C	Rating:	Hold

Overview & Current Events

STERIS plc (STE) is a global leader in infection prevention and other procedural products and services. Founded as Innovative Medical Technologies in Ohio in 1985, the company was later renamed STERIS in 1987. STERIS operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The company has a strong history of acquisitions, including American Sterilizer Company in 1987 and Amsco International in 1996, which expanded its product line for healthcare and sterilization. STERIS has a market capitalization of \$22 billion and a solid history of paying dividends.

On February 5th, 2025, the company announced financial results for the third quarter of fiscal year 2025. STE reported Q3 non-GAAP EPS of \$2.32, in-line with market estimates.

Steris delivered strong fiscal 2025 third-quarter results, with total revenue increasing 6% year-over-year to \$1.4 billion, driven by robust growth in the Healthcare and Applied Sterilization Technologies (AST) segments. Healthcare revenue grew 7% to \$976 million, supported by strong consumable and service revenue growth, while AST revenue surged 10% to \$258.1 million. Despite a 7% decline in Life Sciences revenue due to a divestiture and lower capital equipment sales, segment operating income improved, highlighting a favorable business mix.

Looking ahead, STERIS updated its fiscal 2025 guidance, expecting reported revenue growth of approximately 6%, slightly lower than previous projections due to unfavorable currency fluctuations and softer capital equipment sales in the Healthcare segment. Adjusted EPS is now projected in the range of \$9.05 to \$9.15, with free cash flow estimated at \$700 million. The company remains confident in its operational strength and long-term growth strategy, emphasizing disciplined capital allocation and continued investments in innovation.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$2.25	\$1.56	\$1.28	\$3.39	\$3.55	\$4.76	\$4.63	\$2.48	\$1.07	\$3.81	\$9.10	\$11.61
DPS	\$0.90	\$0.98	\$1.09	\$1.21	\$1.33	\$1.45	\$1.57	\$1.69	\$1.84	\$2.03	\$2.28	\$3.67
Shares¹	59.4	70.7	85.5	85.0	84.6	84.8	85.2	97.5	99.7	98.8	100.0	134.8

STERIS plc operates in a growing healthcare industry that will positively influence its revenues over the long term. In addition, it has a strong track record of growth through acquisitions that helped expand its product offerings and geographical reach. For example, the acquisition of Cantel Medical expanded its product portfolio in infection prevention.

The most significant development for STERIS plc in 2023 was the completion of several tuck-in acquisitions. These acquisitions expanded their product and service offerings in the AST and Healthcare segments. The total aggregate consideration for these acquisitions was approximately \$49.8 million, including a potential contingent consideration of \$7.3 million. This development allowed STERIS to enhance its capabilities and further strengthen its position in the market.

¹ The shares are in millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated February 19th, 2025, by Yiannis Zourmpanos

STERIS plc has reported strong growth in the past five years with an EPS CAGR of 3.6%. We maintain our EPS forecast for 2025, using the midpoint of the management's estimate at \$9.10. Thus, with a forecasted annual growth of 5.0%, close to its long-term average of 6%, the projected EPS in 2030 is \$11.61. STE has consistently increased its DPS but at a slower growth for the last two years. However, we expect the DPS to remain on a rising trajectory through 2030.

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	30.5	20.1	18.5	20.5	22.6	25.7	27.8	27.6	194.8	55.4	24.2	25.0
Avg. Yld.	1.3%	1.4%	1.3%	1.2%	1.0%	0.9%	0.8%	0.8%	0.9%	0.9%	1.0%	1.3%

STERIS plc trades at a forward P/E of 24.2, below its normalized long-term average P/E of around 27.6. STERIS trades below its historical valuation multiples, but we consider a P/E of 25 as a fair reflection of the stock's valuation, suggesting a target price of \$290 by 2030.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	40%	63%	85%	36%	37%	30%	34%	68%	172%	53%	25%	32%

STERIS plc is a leading provider of infection prevention and other healthcare solutions. Its competitive advantage lies in its ability to offer a comprehensive range of products and services that enable healthcare facilities to improve patient outcomes while reducing costs. STERIS plc has also demonstrated resilience during recessions, supported by its steady EPS performance during the 2007 recession. The company has a manageable debt-to-equity ratio of around 36.1%, indicating a healthy balance sheet. This financial stability and competitive edge position STERIS plc for long-term success in the healthcare industry.

Final Thoughts & Recommendation

STERIS' stock has dropped since our last report, but we remain confident that the acquisition synergies will materialize and be reflected in the company's financials in the following years. Thus, our hold rating is premised upon the 6.8% annualized total returns for the medium-term, derived from the forecasted earnings-per-share growth of 5.0%, a 1.0% dividend yield, and a valuation tailwind.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



STERIS plc (STE)

Updated February 19th, 2025, by Yiannis Zourmpanos

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	1,850	2,239	2,613	2,620	2,782	3,031	3,108	4,585	4,958	5,139
Gross Profit	774	895	1,026	1,093	1,175	1,320	1,343	2,016	2,160	2,218
Gross Margin	41.8%	40.0%	39.3%	41.7%	42.2%	43.6%	43.2%	44.0%	43.6%	43.2%
SG&A Exp.	493	627	682	632	670	717	731	1,503	1,299	1,252
Operating Profit	227	212	285	400	442	538	545	426	759	862
Op. Margin	12.3%	9.5%	10.9%	15.3%	15.9%	17.7%	17.6%	9.3%	15.3%	16.8%
Net Profit	135	111	110	291	304	408	397	244	107	378
Net Margin	7.3%	4.9%	4.2%	11.1%	10.9%	13.5%	12.8%	5.3%	2.2%	7.4%
Free Cash Flow	161	128	251	292	350	376	450	397	395	613
Income Tax	74	60	74	63	64	91	121	72	52	150

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	2,097	5,346	4,924	5,200	5,073	5,441	6,574	11,424	10,820	11,060
Cash & Equivalents	168	249	283	202	221	320	221	348	209	207
Acc. Receivable	325	472	483	528	565	586	609	799	928	1,008
Inventories	161	193	198	206	208	264	315	575	695	675
Goodwill & Int.	861	3,280	2,956	3,161	2,928	2,922	3,924	7,733	6,835	6,190
Total Liabilities	1,024	2,308	2,114	1,983	1,887	2,023	2,683	4,879	4,735	4,748
Accounts Payable	99	140	133	136	153	149	157	226	280	252
Long-Term Debt	621	1,568	1,478	1,316	1,183	1,151	1,651	3,088	3,079	3,206
Total Equity	1,072	3,023	2,799	3,206	3,178	3,405	3,881	6,532	6,077	6,302
D/E Ratio	0.58	0.52	0.53	0.41	0.37	0.34	0.43	0.47	0.51	0.51

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	6.8%	3.0%	2.1%	5.7%	5.9%	7.8%	6.6%	2.7%	1.0%	3.5%
Return on Equity	12.8%	5.4%	3.8%	9.7%	9.5%	12.4%	10.9%	4.7%	1.7%	6.1%
ROIC	8.4%	3.5%	2.5%	6.6%	6.8%	9.1%	7.9%	3.2%	1.1%	4.1%
Shares Out.	85.9	85.0	84.8	84.5	84.9	85.4	100.1	100.0	100.3	99.4
Revenue/Share	30.81	31.45	30.35	30.57	32.55	35.39	36.18	46.63	49.46	51.72
FCF/Share	2.68	1.80	2.92	3.41	4.09	4.39	5.24	4.04	3.94	6.17

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.